Last reviewed · How we verify

NCT04423484: GFANEPHRO20

Therapeutic Recommendations for Nephroblastoma

Recruiting now Last updated 2 March 2026
What this trial tests

trial testing Data collection in Nephroblastoma in 1,000 participants. Currently enrolling.

Timeline
1 July 2020
Primary endpoint
31 December 2028
30 December 2030

Quick facts

Lead sponsorFrench Africa Pediatric Oncology Group
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 July 2020
Primary completion31 December 2028
Estimated completion30 December 2030
Sites7 locations across Senegal, Mali, Burkina Faso, Democratic Republic of the Congo, Madagascar, Côte d’Ivoire

Drugs / interventions tested

Conditions studied

Sponsor

French Africa Pediatric Oncology Group

Who can join

Adults 6 Months to 18, any sex, with Nephroblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for Nephroblastoma

Currently open trials in the same condition.

Other French Africa Pediatric Oncology Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04423484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing